Combination therapies targeting PD-1 and CTLA-4 show promise in advanced colorectal cancer, suggesting new treatment avenues.
The combination of PD-1 and CTLA-4 inhibitors in MSI-H/dMMR metastatic colorectal cancer has demonstrated long-term clinical efficacy and a genuine survival benefit. However, in MSS metastatic colorectal cancer, there has been limited response, emphasizing the importance of innovative combination therapies to address both primary and secondary resistance.
No takes yet. Share an insight, caveat, or question.
Sankha Bhattacharya (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: